Search This Blog

Wednesday, May 6, 2026

Ernexa ERNA-101 plus PD-1 achieved complete tumor clearance in ovarian cancer

 

Ernexa Therapeutics reports ERNA-101 plus PD-1 achieved complete tumor clearance, 100% long-term survival in ovarian cancer models

  • Company says ERNA-101 is advancing toward a first-in-human clinical trial following the new preclinical results

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)